Grant: Project Grant
University of Manitoba
$1,071,000.00
Deciphering the Role of ZEB2 transcription factor in B cell Ontogeny and Transformation.
EF 2023-24
Résumé
Blood cancer is a very aggressive form of cancer that affects many Canadian children and adults. This proposal aims to identify new drug combinations to treat aggressive forms of blood cancer. We also aim to determine ways to avoid drug-resistance to these treatments that can sometimes occur during cancer therapy. We will use mouse and patient samples to study top drug combinations and how effective they are in treating these aggressive blood cancers. This project will be important to identify and confirm new drug approaches that can be used in personalized medical care for childhood and adult blood cancer patients in Canada.
Programme
Project Grant
Bénéficiaire
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
499647
Name
Haigh Jody J
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Deciphering the Role of ZEB2 transcription factor in B cell Ontogeny and Transformation.
Programtype2
Operating Grants
Orgnameinp2
University of Manitoba
Cihramount2
$1,071,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Ataqseq; B Cell And B Progenitor Cell Acute Lymphocytic Leukemia; B Cell Development; Epigenetic Regulation; Immunoprecipitation Mass Spec; Mouse Models Of Disease; Patient Derived Xenotransplantation; Rnaseq; Single Cell Rnaseq; Zeb2 Transcription Factor
Abstract
Blood cancer is a very aggressive form of cancer that affects many Canadian children and adults. This proposal aims to identify new drug combinations to treat aggressive forms of blood cancer. We also aim to determine ways to avoid drug-resistance to these treatments that can sometimes occur during cancer therapy. We will use mouse and patient samples to study top drug combinations and how effective they are in treating these aggressive blood cancers. This project will be important to identify and confirm new drug approaches that can be used in personalized medical care for childhood and adult blood cancer patients in Canada.
Competitiondate
202403
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Haigh, Jody J
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,071,000~ $0~
